Quick Answer
Bicara Therapeutics Inc. reported Cash and Equivalents of $96.69 million for fiscal year 2025.
Bicara Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $96.69M | -80.3% |
| 2024 | $489.71M | +112.5% |
| 2023 | $230.44M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $171.67M | -67.0% | -60.7% |
| June 30, 2025 | $436.61M | — | -5.5% |
| March 31, 2025 | $462.06M | — | -5.6% |
| December 31, 2024 | $489.71M | +112.5% | -6.0% |
| September 30, 2024 | $520.76M | — | +126.0% |
| December 31, 2023 | $230.44M | — | — |
- Bicara Therapeutics Inc. showed a decrease of -80.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Bicara Therapeutics Inc.’s cash and equivalents has declined by 58.0% (from $230.44 million to $96.69 million).
- The most recent figure is from Bicara Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: